Correlation Between Oncolytics Biotech and Leveljump Healthcare

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Oncolytics Biotech and Leveljump Healthcare at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncolytics Biotech and Leveljump Healthcare into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncolytics Biotech and Leveljump Healthcare Corp, you can compare the effects of market volatilities on Oncolytics Biotech and Leveljump Healthcare and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncolytics Biotech with a short position of Leveljump Healthcare. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncolytics Biotech and Leveljump Healthcare.

Diversification Opportunities for Oncolytics Biotech and Leveljump Healthcare

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Oncolytics and Leveljump is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Oncolytics Biotech and Leveljump Healthcare Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Leveljump Healthcare Corp and Oncolytics Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncolytics Biotech are associated (or correlated) with Leveljump Healthcare. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Leveljump Healthcare Corp has no effect on the direction of Oncolytics Biotech i.e., Oncolytics Biotech and Leveljump Healthcare go up and down completely randomly.

Pair Corralation between Oncolytics Biotech and Leveljump Healthcare

Assuming the 90 days trading horizon Oncolytics Biotech is expected to under-perform the Leveljump Healthcare. But the stock apears to be less risky and, when comparing its historical volatility, Oncolytics Biotech is 1.3 times less risky than Leveljump Healthcare. The stock trades about -0.01 of its potential returns per unit of risk. The Leveljump Healthcare Corp is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  6.50  in Leveljump Healthcare Corp on October 24, 2024 and sell it today you would lose (1.50) from holding Leveljump Healthcare Corp or give up 23.08% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Oncolytics Biotech  vs.  Leveljump Healthcare Corp

 Performance 
       Timeline  
Oncolytics Biotech 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Oncolytics Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Leveljump Healthcare Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Leveljump Healthcare Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable primary indicators, Leveljump Healthcare is not utilizing all of its potentials. The recent stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Oncolytics Biotech and Leveljump Healthcare Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Oncolytics Biotech and Leveljump Healthcare

The main advantage of trading using opposite Oncolytics Biotech and Leveljump Healthcare positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncolytics Biotech position performs unexpectedly, Leveljump Healthcare can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Leveljump Healthcare will offset losses from the drop in Leveljump Healthcare's long position.
The idea behind Oncolytics Biotech and Leveljump Healthcare Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Fundamental Analysis
View fundamental data based on most recent published financial statements
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance